Tivozanib 1.34 mg Oral Capsule
RxNorm 2534247
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 2534247 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: tivozanib 1.34 mg Oral Capsule.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
SCDPrescribable
Semantic Clinical Drug (SCD):
Tivozanib 1.34 mg Oral Capsule
(Atom ID: 12620243)
FNPrescribable
Full form of descriptor (FN):
Product containing precisely tivozanib (as tivozanib hydrochloride) 1.34 mg/1 each conventional release oral capsule (clinical drug)
(Atom ID: 12727551)
SYPrescribable
Synonym (SY):
Tivozanib (as tivozanib hydrochloride 1.5 mg) 1.34 mg Oral Capsule
(Atom ID: 12620531)
PTPrescribable
Designated preferred name (PT):
Tivozanib (as tivozanib hydrochloride) 1.34 mg oral capsule
(Atom ID: 12727976)
PSNPrescribable
Prescribable Name (PSN):
Tivozanib 1.34 mg Oral Capsule
(Atom ID: 12620249)
Patient Education
Tivozanib
Tivozanib is used to treat advanced renal cell carcinoma (RCC; cancer that begins in the kidneys) that has returned or did not respond to at least two other medications. Tivozanib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop or slow the spread of cancer cells.
[Learn More]
* Please review the disclaimer below.